Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy

Hypertension Research

Volumn 34, Issue 3, 2011, Pages 400-401

  Ogawa, Susumu ^a   Nako, Kazuhiro ^a   Okamura, Masashi ^a   Senda, Miho ^a   Mori, Takefumi ^a   Ito, Sadayoshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ALBUMINURIA; ANTIOXIDANT ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE DURATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; JAPANESE; LETTER; MALE; OXIDATIVE STRESS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ALBUMINURIA; AMIDES; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CHEMOKINE CCL2; CREATININE; DEOXYGUANOSINE; DIABETIC NEPHROPATHIES; FEMALE; FUMARATES; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; OXIDATIVE STRESS; TREATMENT OUTCOME;

EID: 79952427804     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.250     Document Type: Letter

References (10)

1. Düsing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 2009;25: 2287-2301.
2. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension. Hypertens Res 2009;32: 169-175.
3. Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res 2010;33: 62-66.
4. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators: aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358: 2433-2446. (Pubitemid 351793017)
5. Splenser AE, Fisher ND, Danser AH, Hollenberg NK. Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren. J Am Soc Hypertens 2009;3: 315-320.
6. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46: 569-576. (Pubitemid 41376839)
7. Whaley-Connell A, Nistala R, Habibi J, Hayden MR, Schneider RI, Johnson MS, Tilmon R, Rehmer N, Ferrario CM, Sowers JR. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010;298: F655-F661.
8. Chrysant SG. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Drugs Today (Barc) 2010;46: 151-162.
9. Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47: 699-705. (Pubitemid 43740241)
10. Ogawa S, Kobori H, Ohashi N, Urushihara M, Nishiyama A, Mori T, Ishizuka T, Nako K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009;4: 97-102.